Purple Biotech (PPBT) Stock Forecast & Price Target

Purple Biotech Ltd is demonstrating significant progress in its clinical trials, particularly with its oncology pipeline's CM24, which has showcased an objective response rate (ORR) of 25%, substantially higher than the 6.7% seen in control groups. The company's results indicate a 25% reduction in the risk of death among the overall patient population, alongside a notable 2.1-month improvement in median overall survival (OS), indicating strong efficacy in treatment. Additional biomarker analyses from the Phase 2 CM24 trial further highlight positive outcomes, revealing substantial risk reductions in mortality and supporting the potential synergies between CM24 and existing therapies, which collectively contribute to a favorable outlook for Purple Biotech's stock.

Purple Biotech Ltd faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns in its clinical programs, lower-than-expected efficacy, and heightened competition from existing and emerging treatments. The company anticipates a need for approximately $60 million in additional financing by 2037, while its cash runway extends only into the second half of 2025, raising liquidity concerns. Furthermore, the risk of de-listing if shares fall below $1, along with issues related to regulatory decisions and intellectual property protection, compound potential challenges for the company's future growth.